|
|
|
|
|
|
|
|
Expert Reviews - Expert Review of Obstetrics & Gynecology - 7(2):131 - Full Text
ABSTRACT |
---|
Over 150 delegates from the UK, USA and Europe with a core interest in risk prediction and screening for ovarian cancer attended the International Conference on Ovarian Cancer
Screening held on 29–30 November 2011 in London, UK. The scientific
program was driven by two experts in the field – Usha Menon and Ian
Jacobs – with assistance from the scientific committee, which included
Steve Skates, Jatinderpal Kalsi, Anna Lokshin, Uzi Beller, Tim Mould and
Ranjit Manchanda. Over the 2 days, key opinion leaders and researchers
reported on the latest developments, and debated the future of risk
prediction and screening for ovarian cancer.
~~~~~~~~~~~~~
The
conference started with a welcome from Ian Jacobs (University of
Manchester, Manchester, UK), followed by an overview of the current
management of ovarian cancer
(OC) by Tim Mould (University College Hospitals NHS Trust, London, UK).
Stuart Campbell (Create Health Ltd, London, UK), a stalwart in the
field of pelvic ultrasonography, chaired the first session on
differential diagnosis in symptomatic patients. Robert Bast (University
of Texas MD Anderson Cancer
Center, TX, USA), who in the early 1980s discovered CA125, discussed
recent biomarker panels and algorithms (Risk of Malignancy Index [RMI],
Risk of Ovarian
Malignancy Algorithm [ROMA] and OVA1) for OC diagnosis. His view was
that the current challenge, especially in the USA, was implementation so
that OC patients could be operated on by trained gynecological
oncologists. Of the many OC markers, CA125 and HE4 provided the greatest
discrimination between malignant and benign adnexal masses, with the
latter particularly useful in premenopausal women..........cont'd
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.